Background
Methods
Clinical specimens
Characteristics | n = 80 | MCM3AP-AS1 |
P
| ||
---|---|---|---|---|---|
Low expression (n = 40) | High expression (n = 40) | ||||
Age (y) | < 50 | 33 | 14 | 19 | 0.256 |
≥50 | 47 | 26 | 21 | ||
Sex | Male | 65 | 31 | 34 | 0.390 |
Female | 15 | 9 | 6 | ||
HBV | Absent | 25 | 15 | 10 | 0.228 |
Present | 55 | 25 | 30 | ||
Serum AFP level (ng/mL) | < 20 | 24 | 14 | 10 | 0.329 |
≥20 | 56 | 26 | 30 | ||
Tumor size (cm) | < 5 | 30 | 21 | 9 | 0.006* |
≥5 | 50 | 19 | 31 | ||
No. of tumor nodules | 1 | 66 | 34 | 32 | 0.556 |
≥2 | 14 | 6 | 8 | ||
Cirrhosis | Absent | 33 | 19 | 14 | 0.256 |
Present | 47 | 21 | 26 | ||
Venous infiltration | Absent | 49 | 27 | 22 | 0.251 |
Present | 31 | 13 | 18 | ||
Edmondson-Steiner grading | I + II | 60 | 34 | 26 | 0.039* |
III + IV | 20 | 6 | 14 | ||
TNM tumor stage | I + II | 61 | 36 | 25 | 0.004* |
III + IV | 19 | 4 | 15 |
Cell culture
Plasmids and transfection
Quantitative real-time polymerase chain reaction (qRT-PCR)
Gene name | Primer sequences (5′ to 3′) | |
---|---|---|
MCM3AP-AS1 | Forward | GCTGCTAATGGCAACACTGA |
Reverse | AGGTGCTGTCTGGTGGAGAT | |
miR-194-5p | Forward | CTAGTACCTAGAGGAACCTTTGAAGACTGTTACAGCTCAGCA |
Reverse | AGCTTGCTGAGCTGTAACAGTCTTCAAAGGTTCCTCTAGGTA | |
miR-23c | Forward | CCAGAAGGACGTAGAAG |
Reverse | CTTCACTGTGATGGGCTC | |
TRIP12 | Forward | CCGGGGCCCAACCACAAGAC |
Reverse | TGGACGCTGAACGGGAACGC | |
CUL4B | Forward | TGCTGCTCAGGAGGTCAGATC |
Reverse | TGGAATCAAAGTCTTCTCTCTCGTT | |
FOXA1 | Forward | GCAATACTCGCCTTACGGCT |
Reverse | TACACACCTTGGTAGTACGCC | |
BTBD7 | Forward | AGTCAAATGCCTGGTTACGG |
Reverse | TGTCTGGCACATTGGACATT | |
HBEGF | Forward | CCATTCTGAAAGGCTGGTTTG |
Reverse | TACTCCGGAAGGGTCCTTTGT | |
U6 | Forward | GTGGACCGCACAAGCTCGCT |
Reverse | TTGTTGAACGGCACTGTGTATAGCA | |
GAPDH | Forward | CAGGAGGCATTGCTGATGAT |
Reverse | GAAGGCTGGGGCTCATTT |
Western blot analysis
Cell counting Kit-8 (CCK-8) assay
Colony formation assay
Ethynyl deoxyuridine (EdU) incorporation assay
Flow cytometry assay
Tumor xenograft model
Pull-down assay with biotinylated miR-194-5p
RNA immunoprecipitation (RIP)
Luciferase reporter assay
RNA fluorescent in situ hybridization
Quantitation of MCM3AP-AS1 and miR-194-5p expression levels
Statistical analysis
Results
A novel lncRNA MCM3AP-AS1 is overexpressed in HCC
LncRNA | Fold change (tumor vs. normal) | P value | FDR |
---|---|---|---|
FAM99A | 0.04 | 0.000 | 0.010 |
LOC646982 | 0.08 | 0.001 | 0.024 |
DIO3OS | 0.16 | 0.005 | 0.061 |
PWRN1 | 0.31 | 0.010 | 0.096 |
LOC286002 | 0.43 | 0.005 | 0.061 |
NEAT1 | 0.45 | 0.009 | 0.094 |
LOC100009676 | 1.79 | 0.003 | 0.044 |
LOC440944 | 1.81 | 0.006 | 0.069 |
TUG1 | 1.83 | 0.005 | 0.061 |
LOC202781 | 1.92 | 0.001 | 0.024 |
HCG18 | 1.93 | 0.001 | 0.024 |
DGCR11 | 2.18 | 0.002 | 0.031 |
SNHG12 | 2.27 | 0.002 | 0.035 |
LOC728190 | 2.29 | 0.006 | 0.068 |
LOC100302401 | 2.33 | 0.006 | 0.068 |
SNHG10 | 2.33 | 0.003 | 0.044 |
LOC220930 | 2.34 | 0.008 | 0.088 |
LOC388796 | 2.47 | 0.000 | 0.010 |
LOC100134713 | 2.50 | 0.003 | 0.044 |
LOC100130581 | 2.55 | 0.001 | 0.024 |
LOC100128191 | 2.61 | 0.008 | 0.081 |
C6orf164 | 2.83 | 0.010 | 0.096 |
MCM3AP-AS1
|
2.84
|
0.001
|
0.024
|
SNHG1 | 2.87 | 0.000 | 0.007 |
SNHG3 | 3.08 | 0.000 | 0.015 |
LOC150381 | 3.08 | 0.005 | 0.061 |
LOC144486 | 4.35 | 0.000 | 0.010 |
LOC541471 | 5.17 | 0.001 | 0.024 |
LOC100133612 | 5.85 | 0.000 | 0.010 |
LOC92659 | 6.44 | 0.000 | 0.007 |
LOC84931 | 6.62 | 0.003 | 0.044 |
LOC284551 | 6.84 | 0.001 | 0.018 |
LOC150197 | 7.00 | 0.003 | 0.044 |
PVT1 | 7.07 | 0.000 | 0.018 |
CDKN2B-AS1 | 7.17 | 0.001 | 0.018 |
LOC286467 | 8.24 | 0.006 | 0.069 |
SNHG4 | 8.64 | 0.000 | 0.007 |